NCT05541159View on ClinicalTrials.gov

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 19, 2025

Primary Completion Date

July 15, 2025

Study Completion Date

July 15, 2025

Conditions
Renal Impairment
Interventions
DRUG

TNO155

Single oral dose of TNO155 on Day 1

Sponsors
All Listed Sponsors
collaborator

Pharmaceutical Research Associates

OTHER

lead

Novartis Pharmaceuticals

INDUSTRY